Bioavailability Study: Clinical Trials

5 trials for Bioavailability Study, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 withdrawn. 4 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Not applicable1Withdrawn 1

Follow Bioavailability Study: new trials by email Literature Review of Bioavailability Study trials Research Report on Bioavailability Study

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.
150 mg trazodone hydrochloride, 300 mg trazodone hydrochloride - Bioavailability Heathy Volunteers, Bioavailability Study
Phase 1CompletedAziende Chimiche Riunite Angelini Francesco S.p.A642024-05-222025-09-03
Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations
Hetrombopag - Bioavailability Study
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.582020-09-182021-02-26
NPC-12G Gel 0.2% Sirolimus PK Bridging Study
NPC-12G Gel 0.2%, Rapamune® 2 mg tablet - Bioavailability Study
Phase 1CompletedNobelpharma122019-05-312020-03-06
A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects
ARGX-113 - Bioavailability Study
Phase 1Completedargenx402017-10-112020-08-31
Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate
MP29-02, Fluticasone propionate - Bioavailability Study
Not applicableWithdrawnUniversity Hospital, Ghent2016-08-012021-07-13

Interventions

Fluticasone (1)  ·  Gels (1)  ·  MP29-02 (1)  ·  Sirolimus (1)  ·  Tablets (1)  ·  Trazodone (1)  ·  efgartigimod alfa (1)  ·  hetrombopag (1)

Sponsors

Aziende Chimiche Riunite Angelini Francesco S.p.A (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  Nobelpharma (1)  ·  University Hospital, Ghent (1)  ·  argenx (1)

Countries

Belgium (1)  ·  China (1)  ·  Germany (1)  ·  Netherlands (1)  ·  United States (1)

Top investigators

Claus Bachert (1)  ·  Thierry Cousin, MD (1)

Results publications

PMID 39636455

NIH funding

2015 (1)